BrianGillBarnettMD

Breast Cancer, Hematologic Oncology

Medical Director/Genentech

Dr. Barnett is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
17050 Medical Center Dr
Baton Rouge, LA 70816
Phone+1 225-755-3070

Fax+1 225-755-3085

Tulane UniversityFellowship, Hematology and Medical Oncology, 2004 - 2006
Tulane UniversityResidency, Internal Medicine, 2002 - 2004
University of Mississippi Medical CenterInternship, Internal Medicine, 1998 - 1999
University of Mississippi School of MedicineClass of 1998

PubMed

125 citations
Targeted adenoviral vectors.
Brian G. Barnett, C.Jefferson Crews, Joanne T. Douglas
Biochimica Et Biophysica Acta. 2002-05-03
112 citations
The therapeutic efficacy of adenoviral vectors for cancer gene therapy is limited by a low level of primary adenovirus receptors on tumour cells.
Myunghee Kim, Kurt R. Zinn, Brian G. Barnett, L. A. Sumerel, Victor Krasnykh
European Journal of Cancer. 2002-09-01
333 citations
Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals.
Linhua Zou, Brian G. Barnett, Hana Safah, Vincent F. LaRussa, Melina Evdemon-Hogan
Cancer Research. 2004-11-15

Cleveland Clinic Enters into Collaboration to Acquire Psilocybin, DMT and MDMA for Clinical InvestigationApril 20th, 2020
OncBioMune Pharmaceuticals, Inc. (OTCMKTS:OBMP) Files an 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersMarch 19th, 2019
Dr. Mitesh Borad Joins OncBioMune Scientific Advisory BoardJanuary 28th, 2019
Join now to see all